Stockscreener 앱 받기
0.1916
0.26%
-0.0005
시간 외 거래:
.20
0.0084
+4.38%
전일 마감가:
$0.1921
열려 있는:
$0.181
하루 거래량:
818.60K
Relative Volume:
2.74
시가총액:
$8.01M
수익:
$20.27M
순이익/손실:
$-63.80M
주가수익비율:
-0.1261
EPS:
-1.52
순현금흐름:
$-68.35M
1주 성능:
-41.94%
1개월 성능:
-52.11%
6개월 성능:
-79.72%
1년 성능:
-90.02%
1일 변동 폭
$0.17
$0.224
1주일 범위
$0.17
$0.37
52주 변동 폭
$0.17
$2.0497
Carisma Therapeutics Inc Stock (CARM) Company Profile
명칭
Carisma Therapeutics Inc
전화
(267) 491-6422
주소
3675 MARKET STREET, PHILADELPHIA
CARM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CARM
Carisma Therapeutics Inc
|
0.1916 | 8.01M | 20.27M | -63.80M | -68.35M | -1.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-12-10 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-04-11 | 개시 | BTIG Research | Buy |
| 2023-10-03 | 개시 | CapitalOne | Overweight |
| 2023-07-06 | 개시 | Evercore ISI | Outperform |
| 2023-05-31 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-05-24 | 개시 | H.C. Wainwright | Buy |
| 2023-04-14 | 개시 | Robert W. Baird | Outperform |
모두보기
Carisma Therapeutics Inc 주식(CARM)의 최신 뉴스
Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace
Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan - MyChesCo
Philly’s Carisma Therapeutics slashed its workforce to 6 from 46 for sale or wind down - MSN
Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Carisma Therapeutics (NASDAQ:CARM) Price Target Lowered to $1.00 at D. Boral Capital - Defense World
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Carisma Therapeutics to Present at AASLD 2024 on Liver Fibrosis Treatment - MSN
Penn spinout Carisma Therapeutics lays off 84% of its staff, explores possible sale - The Business Journals
Carisma Therapeutics Provides Corporate Updates - Citizen Tribune
Carisma Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Carisma Therapeutics Board Approves Revised Operating Plan; Reduces Workforce - MarketScreener
Carisma Therapeutics Inc. SEC 10-K Report - TradingView
Carisma Therapeutics Explores Sale Options as Company Halts R&D Programs - Stock Titan
Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry - simplywall.st
Carisma Therapeutics (CARM) to Release Earnings on Monday - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of “Hold” from Analysts - Defense World
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annua - GuruFocus.com
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Michael Klichinsky to Speak at H.C. Wainwright Cell Therapy Virtual Conference - MSN
Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 - Quantisnow
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Quantisnow
Carisma Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Conference - MSN
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference - Quantisnow
Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
BTIG Downgrades Carisma Therapeutics (CARM) - MSN
Evercore ISI Group Downgrades Carisma Therapeutics (CARM) - MSN
Barclays PLC Has $539,000 Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Carisma Therapeutics (NASDAQ:CARM) Given “Buy” Rating at D. Boral Capital - Defense World
Geode Capital Management LLC Lowers Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Carisma Therapeutics faces Nasdaq delisting over share price - Investing.com India
Carisma Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Average Rating of “Hold” from Analysts - Defense World
Barclays PLC Grows Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023 - GuruFocus.com
4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology - Quantisnow
Carisma Therapeutics Appoints Interim VP of Finance - TipRanks
Carisma Therapeutics Refocuses Strategy, Reduces Workforce Amid Pipeline Reprioritization - MSN
Carisma downgraded by H.C. Wainwright to neutral - MSN
Carisma Therapeutics (NASDAQ:CARM) Given Neutral Rating at HC Wainwright - Defense World
HC Wainwright & Co. Downgrades Carisma Therapeutics (CARM) - MSN
Carisma shares downgraded to neutral after program halt - Investing.com
Carisma Therapeutics Inc (CARM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):